COVID-19 hits a trial: Arguments against hastily deviating from the plan

Area of Science:

• Clinical Trials Methodology
• Epidemiology
• Cardiology

Background:

• The COVID-19 pandemic significantly disrupted ongoing clinical trials globally.
• Assessing and mitigating the pandemic's impact on trial outcomes and data integrity is crucial.
• Variability in pandemic severity and timing across regions complicates trial management.

Purpose of the Study:

• To evaluate methods for assessing the impact of the COVID-19 pandemic on clinical trial outcomes.
• To determine strategies for managing trial irregularities caused by the pandemic.
• To explore the use of simulations for sample size adjustments and treatment effect generalizability.

Main Methods:

• Utilized simulations and theoretical considerations to address pandemic-related challenges in clinical trials.
• Examined a randomized, double-blind trial comparing digitoxin and placebo in advanced chronic heart failure patients.
• Analyzed the potential need for increased sample size to compensate for pandemic-induced shrinkage of treatment effects.

Main Results:

• The pandemic's impact on trial outcomes varies depending on the trial phase and patient population.
• Simulations can inform decisions on sample size adjustments and assess treatment effect consistency.
• Consistency of treatment effects across pre-, during-, and post-pandemic periods is key for generalizability.

Conclusions:

• In the face of uncertainty, adhering to the original clinical trial plan may be the most prudent approach.
• Careful consideration of pandemic impact and consistency analysis is essential for valid trial results.
• Methodologies are proposed to navigate and validate clinical trials conducted during the COVID-19 pandemic.